Compare MELI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MELI | SNY |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Uruguay | France |
| Employees | N/A | 74846 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3B | 107.3B |
| IPO Year | 2007 | N/A |
| Metric | MELI | SNY |
|---|---|---|
| Price | $1,820.45 | $47.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 5 |
| Target Price | ★ $2,725.29 | $58.00 |
| AVG Volume (30 Days) | 399.8K | ★ 2.9M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.33% |
| EPS Growth | ★ 4.54 | N/A |
| EPS | ★ 39.40 | N/A |
| Revenue | ★ $28,893,000,000.00 | N/A |
| Revenue This Year | $35.51 | $3.86 |
| Revenue Next Year | $24.29 | $5.64 |
| P/E Ratio | $47.56 | ★ $6.14 |
| Revenue Growth | ★ 39.06 | N/A |
| 52 Week Low | $1,593.21 | $43.32 |
| 52 Week High | $2,645.22 | $55.73 |
| Indicator | MELI | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 58.76 |
| Support Level | $1,626.21 | $46.88 |
| Resistance Level | $2,128.30 | $48.49 |
| Average True Range (ATR) | 58.20 | 0.71 |
| MACD | 25.71 | 0.12 |
| Stochastic Oscillator | 76.18 | 74.45 |
MercadoLibre runs the largest e-commerce marketplace in Latin America, with about 150 million active users and more than 600 million active listings across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.